1357089-53-2

Upstream product

• 299203-59-1 ethyl 5-(4-cyanophenyl)-2-furancarboxylate 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 1357089-49-6 C₃₃H₃₀N₄O₈ 
• 1312579-02-4 C₁₉H₁₉N₃O₅ 
• 1357089-51-0 C₃₃H₃₂N₄O₆ 

Downstream Products

• 1357089-54-3 C₃₁H₂₆N₄O₄ 
• 1312578-81-6 C₂₃H₂₀N₄O₂ 
• 1357089-40-7 C₂₅H₂₁N₅O 
• 1357089-42-9 C₂₄H₂₀N₆O 
• 1435946-86-3 C₃₆H₂₉FN₄O₂ 
• 1435946-87-4 C₃₅H₂₈FN₅O₂ 
• 1435946-88-5 C₃₆H₃₁N₅O₃ 
• 1435946-89-6 C₃₅H₂₉N₅O₂ 
• 1435946-90-9 C₃₆H₃₁N₅O₃ 
• 1435946-91-0 C₃₆H₃₁N₅O₃ 
• 1312578-88-3 C₃₄H₂₈N₆O₂ 

Relevant academic research and scientific papers

Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors

Conformation restriction of linear N-alkylanilide MK2 inhibitors to their E-conformer was developed. This strategy enabled rapid advance in identifying a series of potent non-ATP competitive inhibitors that exhibited cell based activity in anti-TNFα assay.

Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors

Facile synthesis of two new series of tetracyclic azepine and oxazocine analogs is described. These analogs were evaluated for their potential as MAPKAP-K2 (MK2) inhibitors and several were found to be potent at inhibiting MK2 with a non-ATP competitive binding mode.